Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zaps for anxiety? small study tests new target

NCT ID NCT06475040

Symptom relief Sponsor: Shanghai Mental Health Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a new type of brain stimulation, called accelerated intermittent theta burst stimulation (aiTBS), for people with anxiety disorders or PTSD. Fifteen participants received the non-invasive treatment targeting a novel brain area. The study measured changes in anxiety symptoms using standard questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial magnetic stimulation (TMS)
What this could lead to
If it works, this could point toward a new, non-invasive brain stimulation treatment for anxiety and trauma-related disorders.
What could go wrong
This is a very small pilot study with only 15 participants, so results may not apply to everyone. It is early-stage research, and the treatment may not prove effective in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Jun 2024

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosis of generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder (PD), and/or post-traumatic stress disorder (PTSD) as defined by DSM-5 criteria. 2. Male or female between 18 and 60 years old. 3. Right-handed. 4. Can understand and sign an informed consent document. 5. Beck Anxiety Inventory (BAI) score of 16 or higher. 6. On a stable medication/psychotherapy regimen for at least 6 weeks prior to baseline visit and throughout the duration of the study. 7. In good general health, as ascertained by medical history. 8. Pharmacological treatment resistance or psychotherapeutic treatment resistance. Exclusion Criteria: 1. Substance use disorders, eating disorders, significant suicidal ideation, mental disorder due to a medical or neurocognitive condition, lifetime psychosis, bipolar disorder, developmental disorders. 2. History of brain surgery and epilepsy. 3. Presence of metallic foreign bodies, such as cardiac pacemakers and stents. 4. Any medical condition or medication that increases the risk of seizures. 5. Pregnancy. 6. Intellectual disability. 7. Current severe somatic disease, such as cancer, heart failure, pneumonia, etc. 8. Severe claustrophobia that prevents the use of MRI.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder generalized anxiety disorder panic disorder post-traumatic stress disorder social phobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety disorders Anxiety symptoms

Contacts and locations

Locations

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, 200030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.